NEW YORK: W2O Group veteran Steph Glickman has joined Pfizer Innovative Health as director of communications.
She started at the drug maker last month, according to her LinkedIn profile. A Pfizer spokesperson confirmed she is working at the pharma company, but declined to comment further. Glickman could not be immediately reached for comment.
Prior to joining Pfizer, Glickman was group director at W2O Group for more than two years. She also spent nearly seven years as VP at Ruder Finn and worked at MSLGroup predecessor MS&L Worldwide.
In September, the pharmaceutical giant decided not to split its Innovative Health and Essential Health units into two separate companies. Innovative Health develops newer drugs such as atrial fibrillation treatment Eliquis and Xeljanz, a drug used to treat rheumatoid arthritis, while Essential Health manages older, off-patent drugs.
Earlier this year, Pfizer’s proposed merger with Ireland-based pharma giant Allergan was halted over tax-inversion concerns, stopping what would have been a $160 billion merger.
Pfizer’s revenues were up 8% in the third quarter to $13 billion, but the company missed analysts’ expectations. It blamed expiring patents for antibiotic Zyvox and muscle-pain treatment Lyrica.
The company said on Thursday that it is partnering with IBM’s Watson Health to discover potential drugs.
